Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats

Toxicology

Volumn 116, Issue 1-3, 1997, Pages 77-88

  Henry, Scott P ^a   Grillone, Lisa R ^a   Orr, Jack L ^b   Bruner, Richard H ^c   Kornbrust, Douglas J ^d  

^a ISIS PHARMACEUTICALS   (United States)

^b South West Research Institute ^*  (United States)

^c Pathology Associates Inc   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antisense; Phosphorothioate deoxyoligonucleotide; Rat; Toxicology

Indexed keywords

AFOVIRSEN; ALBUMIN; AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; ISIS 1082; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOXICITY; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; HISTOPATHOLOGY; INJECTION SITE; INTRADERMAL DRUG ADMINISTRATION; LIVER METABOLISM; LIVER WEIGHT; LYMPHOID HYPERPLASIA; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN WEIGHT; THROMBOCYTOPENIA; WEIGHT GAIN;

ANIMALS; BASE SEQUENCE; FEMALE; INJECTIONS, INTRADERMAL; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOTIDES;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0031036843     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(96)03532-9     Document Type: Article

References (12)

1. Agrawal, S., Temsmani, J., and Tang J.Y. (1991) Pharmacokinetics, biodistribution, and stability of oligonucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
2. Cossum, P.A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S.R., Markham, P.M., Shea, J.P. and Crooke, S.T. (1994a) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
3. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
4. Crooke, R.M. (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 6, 609-646.
5. Crooke, S.T. (1992) Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376.
6. Henry, S.P., Taylor, J., Midgley, L., Levin, A.A. and Kornbrust, D.J. (1996) Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide. 1. 4-Week study in CD-1 Mice. Arch. Toxicol. (submitted for publication).
7. Iverson, P. (1991) In vivo studies with phosphorothioates oligonucleotides: pharmacokinetics prologue. Anti-Cancer Drug Design 6, 531-538.
8. Iverson, P. (1993) In vivo studies with phosphorothioate oligonucleotides: rationale for systemic therapy. In: S.T. Crooke and B. Lebleu (Eds), Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 461-469.
9. Krieg, A.M., Yi, A., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A. and Klinman, D.M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549.
10. Saijo, Y., Perlaky, L., Wang, H. and Busch, H. (1994) Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxyribonucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6, 243-249.
11. Sarmiento, U.M., Perez, J.R., Becker, J.M. and Narayana, R. (1994) In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev. 4, 99-107.
12. Stein, C.A. and Cheng, Y.-C. (1993) Antisense oligonucleotides as therapeutic agents. Is the bullet really magic? Science 261, 1004-1012.